María del Pilar
Herrera Puente
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen del Rocío (21)
2024
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
HemaSphere
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Transplantation and Cellular Therapy, Vol. 28, Núm. 5, pp. 258.e1-258.e8
-
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295
-
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain
Leukemia and Lymphoma
2021
-
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Cancer, Vol. 127, Núm. 12, pp. 2003-2014
-
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 10, pp. e801-e809
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
2015
-
Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia
Annals of Hematology, Vol. 94, Núm. 8
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300